American Association for Cancer Research
00085472can122301-sup-f6_65k.pdf (65.38 kB)

Supplementary Figure 6 from Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence

Download (65.38 kB)
journal contribution
posted on 2023-03-30, 21:47 authored by Pier Davide Angelini, Mariano F. Zacarias Fluck, Kim Pedersen, Josep Lluís Parra-Palau, Marc Guiu, Cristina Bernadó Morales, Rocio Vicario, Antonio Luque-García, Nerea Peiró Navalpotro, Jordi Giralt, Francesc Canals, Roger R. Gomis, Josep Tabernero, José Baselga, Josep Villanueva, Joaquín Arribas

PDF file - 65K, Growth of a mixture 1:1 of MCF7 Tet-off / p95HER2 and MDA-MB-231 / Luc cells in the presence or absence of doxycycline



Senescence, a terminal cell proliferation arrest, can be triggered by oncogenes. Oncogene-induced senescence is classically considered a tumor defense barrier. However, several findings show that, under certain circumstances, senescent cells may favor tumor progression because of their secretory phenotype. Here, we show that the expression in different breast epithelial cell lines of p95HER2, a constitutively active fragment of the tyrosine kinase receptor HER2, results in either increased proliferation or senescence. In senescent cells, p95HER2 elicits a secretome enriched in proteases, cytokines, and growth factors. This secretory phenotype is not a mere consequence of the senescence status and requires continuous HER2 signaling to be maintained. Underscoring the functional relevance of the p95HER2-induced senescence secretome, we show that p95HER2-induced senescent cells promote metastasis in vivo in a non–cell-autonomous manner. Cancer Res; 73(1); 450–8. ©2012 AACR.

Usage metrics

    Cancer Research



    Ref. manager